Effect of antithymocyte globulin induction treatment on renal transplant outcome.
Servicio de Nefrologia, Hospital Clinico de San Carlos, Madrid, Spain.
A I
AI
Sanchez-Fructuoso
P
P
Naranjo
J
J
Torrente
C
C
Fernández-Pérez
B
B
Avilés
D
D
Prats
A
A
Barrientos
D000328:Adult; D000367:Age Factors; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents